Business
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially
About this update from Lifecore Biomedical, Inc.
[{"type":"text","content":"-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore’s High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer. This customer is a publicly traded U.S.-based pharmaceutical company that has successfully developed multiple marketed products, and continues to advance a pipeline toward commercialization. One of the agreements is a commercial site transfer under which Lifecore will manufacture a currently marketed product that, until now, has been produced by another CDMO. While this agreement has been signed with an existing customer, this is a new product to Lifecore. The company will perform technical transfer services including process performance qualification (“PPQ”) batches at commercial scale. Upon successful completion of all regulatory requirements, the agreement calls for Lifecore to initiate commercial manufacture of this product. The second agreement with the same existing customer provides for the expansion of services. Lifecore currently manufactures this commercial product for the treatment of ophthalmic-related diseases in one format and will now begin to manufacture it in a second delivery system. This additional delivery modality is currently manufactured in Europe. “On the heels of another commercial site transfer agreement announced earlier this week, we are very pleased to announce the signing of these two new agreements during DCAT week,” said Paul Josephs, chief executive officer of Lifecore. “The commercial site transfer, which is the fourth we’ve signed in the last five months, is a testament to Lifecore’s successful new commercial strategy and our prioritization of such transfer programs, which present a higher probability of approval than earlier stage development programs. We believe this high-value ...